Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Goodman

Brown

Edwards

. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494–502.

Dunn

Blight

. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011; 27: 1415–1423.

Samar

Metz

. Criterion validity of speech intelligibility rating scale procedures for the hearing-impaired population. J Speech Hear Res 1988; 31: 307–316.

Rochester Institute of Technology www.rit.edu/ntid/speechlang/slpros/assessment/intel/sentence. (accessed 28 May, 2012).